ZA202004638B - Antagonists of the muscarinic acetylcholine receptor m4 - Google Patents
Antagonists of the muscarinic acetylcholine receptor m4Info
- Publication number
- ZA202004638B ZA202004638B ZA2020/04638A ZA202004638A ZA202004638B ZA 202004638 B ZA202004638 B ZA 202004638B ZA 2020/04638 A ZA2020/04638 A ZA 2020/04638A ZA 202004638 A ZA202004638 A ZA 202004638A ZA 202004638 B ZA202004638 B ZA 202004638B
- Authority
- ZA
- South Africa
- Prior art keywords
- antagonists
- acetylcholine receptor
- muscarinic acetylcholine
- muscarinic
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625656P | 2018-02-02 | 2018-02-02 | |
| PCT/US2019/016300 WO2019152809A1 (en) | 2018-02-02 | 2019-02-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202004638B true ZA202004638B (en) | 2023-02-22 |
Family
ID=67480022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04638A ZA202004638B (en) | 2018-02-02 | 2020-07-27 | Antagonists of the muscarinic acetylcholine receptor m4 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11414406B2 (https=) |
| EP (1) | EP3746421B1 (https=) |
| JP (1) | JP7352294B2 (https=) |
| KR (1) | KR20200116945A (https=) |
| CN (1) | CN111788182B (https=) |
| AU (1) | AU2019216492A1 (https=) |
| CA (1) | CA3090130A1 (https=) |
| IL (1) | IL276411B2 (https=) |
| WO (1) | WO2019152809A1 (https=) |
| ZA (1) | ZA202004638B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018300980A1 (en) | 2017-07-12 | 2020-01-02 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CA3155864A1 (en) * | 2019-10-04 | 2021-04-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| MX2022010634A (es) * | 2020-02-28 | 2023-01-19 | Remix Therapeutics Inc | Derivados de piridazina para modular el empalme de acidos nucleicos. |
| WO2022111500A1 (en) | 2020-11-26 | 2022-06-02 | Rezubio Pharmaceuticals Co., Ltd | Anticholinergic agents |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| DE60225195T2 (de) * | 2002-12-23 | 2009-02-26 | Ranbaxy Laboratories, Ltd. | Flavaxat-derivate als muscarin-rezeptor antagonisten |
| EP1618091A1 (en) | 2003-04-09 | 2006-01-25 | Ranbaxy Laboratories, Ltd. | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2006035280A1 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| EP1796667A2 (en) * | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US20080255188A1 (en) | 2005-07-11 | 2008-10-16 | Naresh Kumar | Muscarinic Receptor Antagonists |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| CA2672373C (en) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN101230058A (zh) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| CN103102352B (zh) | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| JP2017516850A (ja) * | 2014-05-23 | 2017-06-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物 |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| BR112018008630A2 (pt) | 2015-11-06 | 2018-10-30 | Neurocrine Biosciences Inc | derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica |
| IL294124B2 (en) | 2015-12-10 | 2024-02-01 | Ptc Therapeutics Inc | Methods for treating huntington's disease |
| EP3416639B1 (en) | 2016-02-16 | 2022-06-08 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| JP2020530451A (ja) * | 2017-08-08 | 2020-10-22 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| AU2018352828A1 (en) * | 2017-10-17 | 2020-04-23 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL273924B2 (en) | 2017-10-20 | 2024-07-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019126559A1 (en) * | 2017-12-20 | 2019-06-27 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
-
2019
- 2019-02-01 IL IL276411A patent/IL276411B2/en unknown
- 2019-02-01 CN CN201980012827.5A patent/CN111788182B/zh not_active Expired - Fee Related
- 2019-02-01 US US16/966,306 patent/US11414406B2/en active Active
- 2019-02-01 JP JP2020541908A patent/JP7352294B2/ja active Active
- 2019-02-01 CA CA3090130A patent/CA3090130A1/en active Pending
- 2019-02-01 AU AU2019216492A patent/AU2019216492A1/en not_active Abandoned
- 2019-02-01 WO PCT/US2019/016300 patent/WO2019152809A1/en not_active Ceased
- 2019-02-01 KR KR1020207023725A patent/KR20200116945A/ko not_active Ceased
- 2019-02-01 EP EP19747509.8A patent/EP3746421B1/en active Active
-
2020
- 2020-07-27 ZA ZA2020/04638A patent/ZA202004638B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200116945A (ko) | 2020-10-13 |
| US11414406B2 (en) | 2022-08-16 |
| IL276411B1 (en) | 2023-12-01 |
| CN111788182B (zh) | 2023-09-26 |
| US20200369650A1 (en) | 2020-11-26 |
| IL276411A (en) | 2020-09-30 |
| CA3090130A1 (en) | 2019-08-08 |
| EP3746421A4 (en) | 2021-10-27 |
| JP7352294B2 (ja) | 2023-09-28 |
| EP3746421B1 (en) | 2023-11-29 |
| IL276411B2 (en) | 2024-04-01 |
| EP3746421A1 (en) | 2020-12-09 |
| AU2019216492A1 (en) | 2020-08-20 |
| WO2019152809A1 (en) | 2019-08-08 |
| CN111788182A (zh) | 2020-10-16 |
| JP2021513519A (ja) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273924A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| IL271805A (en) | M4 muscarinic acetylcholine receptor antagonists | |
| IL274062A (en) | Muscarinic acetylcholine M4 receptor antagonists | |
| IL276411A (en) | M4 muscarinic acetylcholine receptor antagonists | |
| ZA201808219B (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| IL291951B1 (en) | Muscarinic M1 acetylcholine receptor antagonists | |
| ZA202007986B (en) | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor | |
| EP3732163A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
| HUE058759T2 (hu) | Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával | |
| EP3697781C0 (en) | MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS | |
| EP4037677A4 (en) | ANTAGONISTS OF THE MUSCARIC ACETYLCHOLINE RECEPTOR M4 | |
| HUE058217T2 (hu) | Új bradikinin B2 receptor antagonisták | |
| EP3665175A4 (en) | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS | |
| IL277144A (en) | Adenosine receptor antagonists and uses thereof | |
| EP3846806A4 (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| IL279960A (en) | P2X3 receptor antagonists | |
| GB201815629D0 (en) | Antagonists | |
| GB201702174D0 (en) | Orexin receptor antagonists | |
| SI3523310T1 (sl) | Kristalinični polimorfi agonista muskarinskega acetilholinskega receptorja | |
| GB201707499D0 (en) | Orexin receptor antagonists | |
| HK40052415A (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| HK40077302A (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| HK40042180A (en) | P2x3 receptor antagonists | |
| SG11202105784WA (en) | Antagonists | |
| HK40043168A (en) | Heterocyclic p2y14 receptor antagonists |